These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 30039176

  • 1. [What gnaws at the heart and gets on the nerves].
    Kristen AV.
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [Abstract] [Full Text] [Related]

  • 2. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 3. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 4. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H, Hashimoto T, Kawamura S, Hiroe M, Yamashita T, Ando Y, Yokochi T.
    J Med Case Rep; 2018 Dec 16; 12(1):370. PubMed ID: 30553273
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M, Yabe I, Tsuda M, Sakakibara M, Shimamura T, Sasaki H.
    Intern Med; 2017 Dec 01; 56(23):3231-3235. PubMed ID: 28943540
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May 01; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 11. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L.
    Amyloid; 2017 Mar 01; 24(1):30-36. PubMed ID: 28393570
    [Abstract] [Full Text] [Related]

  • 12. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M, Norman K, Sanchorawala V, Siddiqi OK, Hughes D.
    J Cardiovasc Pharmacol; 2021 May 01; 77(5):544-548. PubMed ID: 33657048
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S, Rossello A, Orlandini E.
    ChemMedChem; 2013 Oct 01; 8(10):1617-9. PubMed ID: 24000164
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tafamidis for transthyretin amyloidosis.
    de Lartigue J.
    Drugs Today (Barc); 2012 May 01; 48(5):331-7. PubMed ID: 22645721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.